Responders and Non-responders in the Management of Heart Failure - Significance of Genetic Influence and Identification of Novel Informative Biomarkers

Launched by KAROLINSKA UNIVERSITY HOSPITAL · May 24, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how genetic factors and new biomarkers (substances in the body that can indicate health conditions) influence the treatment of heart failure. Heart failure is a condition where the heart cannot pump blood effectively, leading to symptoms like fatigue and shortness of breath. Researchers want to learn more about why some patients respond well to treatments while others do not. This study is part of a larger project in Sweden that collects health information from people with heart failure to improve patient care.

To participate in this trial, individuals must be between the ages of 65 and 74 and have heart failure as diagnosed by a doctor. They also need to give written consent to join the study and be registered in a national heart failure quality registry called SwedeHF. Participants will be asked to provide blood samples, so those who have recently donated blood or have certain health concerns may not be eligible. If you join the study, you can expect to contribute to important research that could help improve treatment for heart failure in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent
• • 2. Heart failure defined by symptoms and signs of heart failure as judged by the local investigator
• • 3. Registered in SwedeHF
• Exclusion Criteria:
• • 1. Plasma donation within 1 month of enrolment or any blood donation/blood loss \>500 mL during the 3 months prior to enrolment
• • 2. Previous allogeneic bone marrow transplant (genetics)
• • 3. In the opinion of the investigator, condition/s that may either put the patient at risk on participation or influence the results or the patient's ability to participate in the study.